The DOI matches its Crossref record.
Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.
Abstract
In 1993, the Health Services Research Committee of the American Society of Clinical Oncology (ASCO) charged an Outcomes Working Group with defining the outcomes of adult and pediatric cancer treatment to be used for technology assessment and development of cancer treatment guidelines. The Working Group defined by consensus outcomes for technology assessment and guideline development, focusing on cancer treatments. The Working Group considered a variety of perspectives on outcomes, including those of patients, physicians, clinical investigators, ASCO, and policy makers. Because ASCO's guidelines will define what constitutes the best treatment and not whether that treatment should be paid for, the Working Group gave higher priority to the clinical and clinical research perspectives than to the health policy perspective. Survival is the most important outcome of cancer treatment. An improvement in at least disease-free survival is a prerequisite for recommending adjuvant therapy. In the case of metastatic cancer, treatment can be recommended even without an improvement in survival, if it improves quality of life. Quality of life includes global quality of life, as well as its physical, psychologic, and social dimensions. To be an outcome of cancer treatment, quality-of-life measures must be sensitive to clinically meaningful changes produced by treatment; evaluations must control for placebo effects and determinants of quality of life not related to cancer or its treatment. Toxicity, both short and long term, is vitally important, with the latter being particularly critical in children. The value of cancer outcomes like tumor response (eg, complete or partial response) and biomarkers (eg, CA-125) for technology assessment and guideline development depends on their ability to predict patient outcomes (survival and quality of life) or to influence decisions about treatment. Complete response is an important outcome when it predicts survival. Progression is important because it signals the need to change or stop treatment. Cost-effectiveness is an especially important outcome to consider when the benefits of treatment are modest or the costs are high. Patient outcomes (eg, survival and quality of life) should receive higher priority than cancer outcomes (eg, response rate), but both types of outcomes are important in technology assessment and guideline development. Multiple outcomes should be considered because no single outcome adequately describes the results of cancer treatment. In general, there is no minimum benefit above which treatments are justified; rather, benefits should be balanced against toxicity and cost.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Aaronson, N. K., Muller, M., Cohen, P. D. A., Essink-Bot, M.-L., Fekkes, M., Sanderman, R., Sprangers, M. A. G., te Velde, A., & Verrips, E. (1998) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(98)00097-3 · Cited by 2,276
Smith, T. J., Khatcheressian, J., Lyman, G. H., Ozer, H., Armitage, J. O., Balducci, L., Bennett, C. L., Cantor, S. B., Crawford, J., Cross, S. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4451 · Cited by 1,636
Gupta, K., Miller, J. D., Li, J. Z., Russell, M. W., & Charbonneau, C. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.12.001 · Cited by 974
Bast, R. C., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., & Somerfield, M. R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1865 · Cited by 879
Recht, A., Edge, S. B., Solin, L. J., Robinson, D. S., Estabrook, A., Fine, R. E., Fleming, G. F., Formenti, S., Hudis, C., Kirshner, J. J., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1539 · Cited by 816
Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer
Budd, G. T., Cristofanilli, M., Ellis, M. J., Stopeck, A., Borden, E., Miller, M. C., Matera, J., Repollet, M., Doyle, G. V., Terstappen, L. W. M. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1769 · Cited by 775
Landier, W., Bhatia, S., Eshelman, D. A., Forte, K. J., Sweeney, T., Hester, A. L., Darling, J., Armstrong, F. D., Blatt, J., Constine, L. S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.032 · Cited by 706
Glaspy, J., Bukowski, R., Steinberg, D., Taylor, C., Tchekmedyian, S., & Vadhan-Raj, S. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.1218 · Cited by 693
Schnipper, L. E., Smith, T. J., Raghavan, D., Blayney, D. W., Ganz, P. A., Mulvey, T. M., & Wollins, D. S. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8375 · Cited by 649
Immunotherapy for advanced renal cell cancer
Coppin, C., Porzsolt, F., Autenrieth, M., Kumpf, J., Coldman, A., & Wilt, T. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001425.pub2 · Cited by 589
RetractedKhatcheressian, J. L., Wolff, A. C., Smith, T. J., Grunfeld, E., Muss, H. B., Vogel, V. G., Halberg, F., Somerfield, M. R., & Davidson, N. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8575 · Cited by 535
Mechanisms of radiotherapy-associated cognitive disability in patients with brain tumours
Makale, M. T., McDonald, C. R., Hattangadi-Gluth, J. A., & Kesari, S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.185 · Cited by 527
Chau, I., Norman, A. R., Cunningham, D., Waters, J. S., Oates, J., & Ross, P. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.154 · Cited by 524
Di Maio, M., Gallo, C., Leighl, N. B., Piccirillo, M. C., Daniele, G., Nuzzo, F., Gridelli, C., Gebbia, V., Ciardiello, F., De Placido, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.9334 · Cited by 497
Burgers, J. S., Fervers, B., Haugh, M., Brouwers, M., Browman, G., Philip, T., & Cluzeau, F. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.157 · Cited by 463
Rizzo, J. D., Lichtin, A. E., Woolf, S. H., Seidenfeld, J., Bennett, C. L., Cella, D., Djulbegovic, B., Goode, M. J., Jakubowski, A. A., Lee, S. J., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.177 · Cited by 417
Blazeby, J. M., Conroy, T., Hammerlid, E., Fayers, P., Sezer, O., Koller, M., Arraras, J., Bottomley, A., Vickery, C. W., Etienne, P. L., et al. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00270-3 · Cited by 415
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update
Bokemeyer, C., Aapro, M. S., Courdi, A., Foubert, J., Link, H., Österborg, A., Repetto, L., & Soubeyran, P. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2006.10.014 · Cited by 403
Matsuyama, R., Reddy, S., & Smith, T. J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6236 · Cited by 403
Eton, D. T., Cella, D., Yost, K. J., Yount, S. E., Peterman, A. H., Neuberg, D. S., Sledge, G. W., & Wood, W. C. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2004.01.012 · Cited by 390
Bending the Cost Curve in Cancer Care
Smith, T. J., & Hillner, B. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1013826 · Cited by 391
Detmar, S. B., Aaronson, N. K., Wever, L. D. V., Muller, M., & Schornagel, J. H. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.18.3295 · Cited by 347
Acupuncture-point stimulation for chemotherapy-induced nausea or vomiting
Ezzo, J., Richardson, M. A., Vickers, A., Allen, C., Dibble, S., Issell, B. F., Lao, L., Pearl, M., Ramirez, G., Roscoe, J. A., et al. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002285.pub2 · Cited by 341
RetractedHensley, M. L., Schuchter, L., Lindley, C., Meropol, N., Cohen, G., Broder, G., Gradishar, W., Green, D., Langdon, R., Mitchell, R. B., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3333 · Cited by 335
Clinical proteomics: A need to define the field and to begin to set adequate standards
Mischak, H., Apweiler, R., Banks, R. E., Conaway, M., Coon, J., Dominiczak, A., Ehrich, J. H. H., Fliser, D., Girolami, M., Hermjakob, H., et al. (2007) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.200600771 · Cited by 307
The Role of Chemotherapy at the End of Life: “When Is Enough, Enough?”
Harrington, S. E., & Smith, T. J. (2008) · JAMA · doi:10.1001/jama.299.22.2667 · Cited by 280
Heffernan, N., Cella, D., Webster, K., Odom, L., Martone, M., Passik, S., Bookbinder, M., Fong, Y., Jarnagin, W., & Blumgart, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.07.093 · Cited by 279
Molina, R., Filella, X., Augé, J. M., Fuentes, R., Bover, I., Rifa, J., Moreno, V., Canals, E., Viñolas, N., Marquez, A., et al. (2003) · Tumor Biology · doi:10.1159/000074432 · Cited by 275
Assessing the Clinical Significance of Single Items Relative to Summated Scores
SLOAN, J. A., AARONSON, N., CAPPELLERI, J. C., FAIRCLOUGH, D. L., & VARRICCHIO, C. (2002) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)62218-0 · Cited by 256
Perception of quality of life by patients, partners and treating physicians
Wilson, K. A., Dowling, A. J., Abdolell, M., & Tannock, I. F. (2000) · Quality of Life Research · doi:10.1023/a:1016647407161 · Cited by 254
Smith, T. J., Davidson, N. E., Schapira, D. V., Grunfeld, E., Muss, H. B., Vogel, V. G., & Somerfield, M. R. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.1080 · Cited by 252
Assessing Quality of Life in Adult Cancer Survivors (QLACS)
Avis, N. E., Smith, K. W., McGraw, S., Smith, R. G., Petronis, V. M., & Carver, C. S. (2005) · Quality of Life Research · doi:10.1007/s11136-004-2147-2 · Cited by 223
Winer, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.020 · Cited by 200
Hurkmans, C., Bibault, J.-E., Brock, K. K., van Elmpt, W., Feng, M., David Fuller, C., Jereczek-Fossa, B. A., Korreman, S., Landry, G., Madesta, F., et al. (2024) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2024.110345 · Cited by 110
Metadata
- Venue
- Journal of Clinical Oncology
- Published
- 1996-02
- Volume
- 14
- Issue
- 2
- Pages
- 671-679
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2601846828
- Cited by
- 431
- References
- 0
- FWCI
- 46.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.